6. Lahey FH, Ackerson EB. Retroperitoneal cysts. Ann Surg. 1934;100:231-237.
7. Fletcher C, Unni KK, Mertens F. WHO Classification of Soft Tissue Tumors. In: Fletcher C, Unni KK, Mertens F, editors. Pathology and Genetics: Tumors of Soft Tissue and Bone. World Health Organization Classification of Tumors. International Agency for Research on Cancer Press; 2002. p. 9-12.
8. Greene FL, Page DL, Fleming FD, Fritz A, Balch CM, Haller DG, Morrow M, editores. American Joint Committee on Cancer: Cancer Staging Manual. 6.a ed. New York: Springer; 2002. p. 221-6.
9. Spencer Liles J, Ching Wei D Tzeng, Joshua J Short, Kulesza P, Heslin MJ. Retroperitoneal and Intraabdominal Sarcoma. Curr Probl Surg. 2009;46:445-503.
10. De Schepper AM, Bloem JL. Soft Tissue Tumors. Grading, Staging and Tissue – Specific Diagnosis. Top Magn Reson Imaging. 2007; 18: 431-444.
11. Hueman MT, Ahuja N. Soft tissue sarcoma, Surg Clin N Am. 2008; 88: 451-680.
12. Voros D, Theodorou D, Ventouri K, Prachalias A, Danias N, Gouliamos A. Retroperitoneal Tumors: Do the satellite Tumors Mean Something? Journal of Surgical Oncology, 1998; 68: 30 – 33.
13. Fletcher C, The evolving classification of soft tissue tumors: an update based on the new WHO classification. Histopatology. 2006; 48: 3-12.
14. Fadul D, Fayad LM. Advanced modalities for the imaging of sarcoma. Surg Clin N Am. 2008; 88: 521-537.
15. Verdugo MA. Ultrasonido en el estudio de tumores de partes blandas. Rev Chil Radiol. 2009;15: 5-18.
16. Cogbill TH, Jarman BT. Diagnostic Imaging for General Surgeon. Surg Clin N Am. 2011; 91: 1-276.
17. Nishino M, Hayakawa K, Minami M, Yamamoto A, Ueda H, Takasu K. Primary retroperitoneal neoplasms: CT and MR imaging findings with anatomic and pathologic diagnostic clues. RadioGraphics 2003; 23: 45-57.
18. Francis IR, Cohan RH, Varma DG, Sondak VK. Retroperitoneal sarcomas. Cancer Imaging .2005; 5: 89 – 94.
19. Kilkenny JW III, Bland KI, Copeland EM III: Retroperitoneal sarcoma: The University of Florida experience. J Am Coll Surg. 1996; 182: 329-339.
20. Van Rijswijk CSP, Kunz P, Hogendoorn PCW, Taminiau AHM, Doornbos J, Bloem JL. Diffusion-Weighted MRI in the Characterization of Soft-Tissue Tumors. J Magn Reson Imaging. 2002; 15: 302-307.
21. Schnapauff D, Zeile M, Ben Niederhagen M, Fleige B, Tunn Per-Ulf, Hamm B, Dudeck O. Diffusion-Weighted Echo-Planar Magnetic Resonance Imaging for the Assessment of Tumor Cellularity in Patients With Soft-Tissue Sarcomas. Journal of Magnetic Resonance Imaging. 2009; 29: 1355-59.
22. Coindre JM. Immunohistochemistry in the diagnosis of soft tissue tumous. Histopathology. 2003; 43: 1-16.
23. Ordoñez JL, Osuna D, Garcia-Dominguez DJ, Amaral AT, Otero-Motta AP, Mackintosch C, et al. The clinical relevance of molecular genetics in soft tissue sarcomas. Adv Anat Pathol. 2010; 17: 162-181.
24. Álava E de. Patologia Molecular de los Sarcomas. Oncologia. 2005; 28: 426 – 442.
25. Tolcher AW, Sarantopoulos J, Patnaik A, Phase I, pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol. 2009; 27: 5800-5807
26. Ambrosini G, Cheema HS, Seelman S, Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells. Mol Cancer Ther. 2008;7:890-896.
27. Maki RG, D`Adamo DR, Keohan ML, Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol. 2009;27:3133-3140.
28. Hensley ML, Sill MW, Scribner DR Jr, Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. Gynecol Oncol. 2009; 115: 460-465.
29. George S, Merriam P, Maki RG, Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol. 2009;27:3154-3160.
30. Yuan R, Kay A, Berg WJ, Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol. 2009;2:45.
31. Ordonez JL, Martins AS, Osuna D, Targeting sarcomas: therapeutic targets and their rational. Semin Diagn Pathol. 2008;25:304-316.
32. Muller CR, Paulsen EB, Noordhuis P, Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A. Int J Cancer. 2007;121:199-205.
33. Raut Ch, Pisters P, Retroperitoneal Sarcomas: Combined – Modality Treatment Approaches. J Surg Oncol. 2006; 94 : 81 – 87.
34. Hueman MT, Herman JM, Ahuja N. Management of Retroperitoneal Sarcomas. Surg Clin N Am. 2008; 88: 583-597.
35. Lewis JJ, Leung D, Woodruff JM, Brennan MF. Retroperitoneal Soft – Tissue Sarcoma. Analysis of 500 Patients Treated and Followed at a Single Institution. Ann Surg. 1998;228:355-365.
36. Grimer R, Judson I, Peake D, Seddon B. Guidelines for the management of soft tissue sarcomas. Sarcomas. 2010; 15: 1-15.
37. Stojadinovic A, Leung DHY, Hoss A, Jaques DP, Lewis JJ, Brennan MF, Analisis of the prognostic significance of microscopic margins in 2084 localized primary adult soft tissue sarcomas. Ann Surg. 2002; 235: 424-434.
38. Stoeckle E, Coindre JM, Bonvalot S, et al. Prognostic factors in retroperitoneal
sarcoma: a multivariate analysis of a series of 165 patients of the French Cancer Center Federation Sarcoma Group. Cancer. 2001;92:359-68.
39. Ferrario T, Karakousis CP. Retroperitoneal Sarcomas. Arch Surg. 2003; 38:248-251.
40. Dalton RR, Donohue JH, Mucha P Jr, van Heerden JA, Reiman HM, Chen SP. Management of retroperitoneal sarcomas. Surgery. 1989; 4: 725-732.
41. Catton Ch N, O`Sullivan B, Kotwall C, Cummings B, Hao Y, Fornasier V. Outcomes and prognosis in retroperitoneal soft tissue sarcoma. International Journal of Radiation Oncology. 1994; 29: 1005-1010.
42. Singer S, Corson JM, Demetri GD, Healey EA, Marcus K, Eberlein TJ. Prognostic factors predictive of survival for truncal and retroperitoneal soft-tissue sarcoma. Ann Surg. 1995;221:185-95.
43. Van Doom RC, Gallee MP, Hart AA, Gortzak E, Rutgers EJ, van Coevorden F, Keus RB, Zoetmulder FA. Resecable retroperitoneal sof tissue sarcomas. The effect of extent of resection and postoperative radiation therapy on local tumor control. Cancer. 1994;73: 637-642.
44. Storm FK, Eilber FR, Mirra J, Morton DL. Retroperitoneal sarcomas: a reappraisal of treatment. Journal of Surgical Oncology. 1981; 17: 1-7.
45. Jaques DP, Coit DG, Hajdu SI, Brennan MF, Management of Primary and Recurrent Soft tissue Sarcoma of the Retroperitoneum. Ann Surg. 1990; 212: 51-59.
46. Malerba M, Battista G, Pacelli F, Carriero C, Caprino P, Piccioni E, Crucitti P, Crucitti F. Primary Retroperitoneal Soft Tissue Sarcomas: Results of aggressive surgical treatment. World J Surg 1993; 23: 670-675.
47. Karakousis CP, Kontzoglu K, Driscoll DL. Resecability of retroperitoneal sarcomas: a matter of surgical technique? Eur J Surg Oncol. 1995; 21: 617-622.
48. Mc Grath PC. Retroperitoneal sarcomas. Semin Surg Oncol. 1994;10:364-8.
49. Shibata D, Lewis JJ, Leung DH, Brennan MF. Is there a role for incomplete resection in the management of retroperitoneal liposarcomas? JAm Coll Surg. 2001;193:373-9.
50. Strauss DC, Hayes AJ, Thway K, Moskovic EC, Fisher C, Thomas JM. Surgical management of primary retroperitoneal sarcoma. British Journal of Surgery 2010; 97: 698 – 706.
51. Marin Gomez LM, Vega Ruiz V, Garcia Ureña MA. Sarcomas Retroperitoneales. Aportacion de cinco nuevos casos y revisión de la situación actual. Cir Esp. 2007; 82:172-176.
52. Anaya DA, Lev DC, Pollock RE, The role of surgical margin status in retroperitoneal sarcoma. J Surg Oncol. 2008;98:607-610.
53. Gronchi A, Casali PG, Fiore M, Mariani L, Lo Vullo S, Bertulli R, et al. Retroperitoneal Soft Tissue Sarcomas. Patterns of Recurrence in 167 Patients Treated at a Single Institution. Cancer. 2004; 100: 2448 – 2455.
54. Bonvalot S, Rivoire M, Castaing M, Stoeckle E, Le Cesne A, Blay JY, Laplanche A. Primary retroperitoneal sarcomas: a multivariate analysis of surgical factors associated with local control. J Clin Oncol. 2009; 27: 31.37.
55. Virseda Rodriguez JA, Donate Moreno MJ, Pasto Navarro H, Carrion Lopez P, Martinez Ruiz J, Martinez Sanchiz C, Peran Teruel M. Tumores Retroperitoneales Primarios. Revisión de nuestros casos de los últimos diez años. Arch Esp Urol. 2010;63:13-22.
56. Gronchi A, Lo Vullo S, Fiore M, Musi Ch, Stacchiotti S, Collini P, et al. Aggressive surgical policies in a retrospectively reviewed single-institution case series of retroperitoneal soft tissue sarcoma patients. J Clin Oncol. 2009;27:24-30.
57. Schwarzbach MHM, Hormann Y, Hinz U, Leowardi Ch, Bückler D, Mechtersheimer G, et al. Clinical results of surgery for retroperitoneal sarcoma with major blood vessel involvement. J Vasc Surg. 2006;44:46-55.
58. Medina-Villaseñor EA, Martinez-Macias R, Diaz-Rodriguez L, Barra-Martinez R, de la Garza-Navarro JM, Quezada-Adame I, Neyra-Ortiz E. Sarcomas retroperitoneales. Cir Gen 2006;28:77-82.
59. Fong Y, Coit DG, Woodruff JM, Brennan MF. Lymph node metastasis from soft tissue sarcoma in adults. Analysis of data from a prospective database of 1772 sarcoma patients. Ann Surg. 1993; 217: 72-7.
60. Van Geel AN, Pastorino U, Jauch KW, Judson IR, van Coevorden F, Buesa JM, et al. Surgical treatment of lung metastases: The European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group study of 255 patients. Cancer 1996; 77: 675-682.
61. Sindelar WF, Kinsella TJ, Chen PW, DeLaney TF, Tepper JE, Rosenberg SA, et al.
Intraoperative radiotherapy in retroperitoneal sarcomas. Final results of a prospective,
randomized, clinical trial. Arch Surg 1993;128:402-410.
62. Pawlik TM, Pisters PWT, Mikula L, Feig BW, Hunt KK, Cormier JN, et al. Long-term results of two prospective trials of preoperative external beam radiotherapy for localized intermediate- or high-grade retroperitoneal soft tissue sarcoma. Ann Surg Oncol. 2006;13:508-17.
63. Pisters PW, O"Sullivan B. Retroperitoneal sarcomas: combined modality treatment approaches. Curr Opin Oncol. 2002;14:400-5.
64. Jones JJ, Catton CN, O`Sullivan B, Couture J, Heisler RL, Kandel RA, et al. Initial results of a trial of preoperative external-beam radiation therapy and postoperative brachytherapy for retroperitoneal sarcoma. Ann Surg Oncol 2002;9:346-354.
65. Petersen IA, Haddock MG, Donohue JH, Nagorney DM, Grill JP, Sargent DJ, et al. Use of intraoperative electron beam radiotherapy in the management of retroperitoneal soft tissue sarcomas. Int J Radiat Oncol Biol Phys 2002; 52:469-475.
66. Gieschen HL, Spiro IJ, Suit HD, Ott MJ, Rattner DW, Aucukiewicz ,et al. Long-term results of intraoperative electron beam radiotherapy for primary and recurrent retroperitoneal soft tissue sarcoma. Int J Radiat Oncol Biol Phys 2001;50:127-131.
67. Tzeng CW, Fiveash JB, Popple RA, Arnoletti JP, Russo SM, Urist MM et al. Preoperative radiation therapy with selective dose escalation to the margin at risk for retroperitoneal sarcoma. Cancer 2006;107:371-379.
68. White JS, Biberdorf D, Difrancesco LM, Kurien E, Temple W. Use of tissue expanders and preoperative external beam radiotherapy in the treatment of retroperitoneal sarcoma. Ann Surg Oncol 2007;14:583-590.
69. Zlotecki RA, Katz TS, Morris CG, Lind DS, Hochwald SN. Adjuvant radiation therapy for resecable retroperitoneal soft tissue sarcoma: the University of Florida experience. Am J Clin Oncol 2005;28:310-316.
70. Heslin MJ, Lewis JJ, Nadler E, Newman E, Woodruff JM, Casper ES, et al. Prognostic factors associated with long-term survival for retroperitoneal sarcoma: implications for management. J Clin Oncol. 1997;15:2832-9.
71. Gilbeau L, Kantor G, Stoeckle E, Lagarde P, Thomas L, Kind M, et al. Surgical resection and radiotherapy for primary retroperitoneal sof tissue sarcoma. Radiotherapy and Oncology. 2002 ;65 :137-143.
72. Kaushal A, Citrin D. The Role of Radiation Therapy in the Management of Sarcomas. Surg Clin N Am. 2008; 88: 629 – 646.
73. Thornton K. Chemoterapeutic management of soft tissue sarcoma. Surg Clin N Am. 2008;88: 647-660.
74. Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, et al. Gemcitabine and docetaxel in patients with unresectable lieomyosarcoma: results of a phase II trial. J Clin Oncol. 2002;20:2824-31.
75. Maki RG. Gemcitabine and Docetaxel in metastatic sarcoma: past, present and future. The Oncologist. 2007;12:999-1006.
76. Stojadinovic A, Leung DHY, Hoss A, Jaques DP, Lewis JJ, Brennan MF. Analisis of the prognostic significance of microscopic margins in 2084 localized primary adult soft tissue sarcomas. Ann Surg. 2002;235:424-434.
77. van Dalen T, Hoekstra HJ, van Geel AN, van Coevorden F. Dutch Soft Tissue Sarcoma Group. Locoregional recurrence of retroperitoneal soft tissue sarcoma: second chance of cure forselected patients. Eur J Surg Oncol. 2001;27:564 -568.
78. Hassan I, Park SZ, Donohue JH, Operative Management of Primary Retroperitoneal Sarcomas. A Reappraisal of an Institutional Experience. Ann Surg. 2004; 239:244-250.
79. Bonvalot S, Vanel D, Terrier P, et al. Traitement des récidives des sarcomes retro-péritonéaux. Bull Cancer. 2004;91:845-852.
80. van Dalen T, Hennipman A, Van Coevorden F, Hoekstra HJ, van Geel BN, Slootweg P. Evaluation of a clinically aplicable post-surgical classification system for primary retroperitoneal sofa-tissue sarcoma. Ann Surg Oncol. 2004;11:485-90.
81. Anaya DA, Lahat G, Wang X, Xiao L, Tuvin D, Pisters PW, et al. Establishing prognosis in retroperitoneal sarcoma: a new histology-based paradigm. Ann Surg Oncol. 2009;16:667-675.
82. Bautista N, SuW, O"Connell TX. Retroperitoneal soft-tissue sarcomas: prognosis and treatment of primary and recurrent disease. Am Surg 2000;66:832-6.
83. Chiappa A, Zbar AP, Biffi R, Bellomi M, Orecchia R, Marsiglia H, et al. Primary and recurrent retroperitoneal sarcoma: factors affecting survival and long-term outcome. Hepatogastroenterology 2004;51:1304-1309.
84. Erzen D, Sencar M, Novak J. Retroperitoneal sarcoma: 25 years of experience with aggressive surgical treatment at the Institute of Oncology, Ljubljana. J Surg Oncol 2005;91:1-9.
85. Pacelli F, Tortorelli AP, Rosa F, Papa V, Bossola M, Sanchez AM, et al. Retroperitoneal soft tissue sarcoma: prognostic factors and therapeutic approaches. Tumori. 2008;94:497-504.
86. Gholami S, Jacobs CD, Kapp DS, Parast LM, Norton JA. The value of surgery for retroperitoneal sarcoma. Sarcoma 2009;2009: 605840. Epub 2009 Oct 8.
87. Lehnert T, Cardona S, Hinz U, Willeke, F, Mechtersheimer G, Treiber M, et al. Primary and locally recurrent retroperitoneal soft-tissue sarcoma: local control and survival. Eur J Surg Oncol 2009;35:986-993.
88. Grobmyer SR, Wilson JP, Apel B, Knapik J, Copeland E, Bland K et al. Recurrent retroperitoneal sarcoma: impact of biology and therapy on outcomes. J Am Coll Surg. 2010;210:602-610.
89. Mendenhall WM, Zlotecki RA, Hochwald SN, Hemming AW, Grobmyer SR, Cance WG. Retroperitoneal soft tissue sarcoma. Cancer. 2005;104:669-75.
90. Xu YH, Guo KJ, Guo RX, Ge CL, Tian YL, He SG. Surgical management of 143 patients with adult primary retroperitoneal tumor. World J Gastroenterol 2007; 13: 2619-2621.
91. Windham TC, Pisters PWT. Retroperitoneal sarcomas. Cancer Control. 2005;12:36-43.
92. Potter DA, Glenn J, Kinsella T, et al. Patterns of recurrence in patients with high-grade soft-tissue sarcomas. J Clin Oncol. 1985;3: 353-66.
93. Avancès Ch, Mottet N, Mahatmat A. Prognostic factors for first recurrence in patients with retroperitoneal sarcomas. Urologic Oncology: Seminars and Original Investigations. 2006;24:94-96.
94. Anaya D, Lahat G, Liu J, Xing Y, Cormier JN, Pisters PW, et al. Multifocalidad in retroperitoneal sarcoma. A prognostic factor critical to surgical decisión-making. Ann Surg. 2009;249:137-142.
95. Cheifetz R, Catton C, Kandel R, O"Sullivan B, Couture J, Swallow C. Recent progress in the management of retroperitoneal sarcoma. Sarcoma. 2001;5:17-26.
96. Echenique-Elizondo M, Amondarain-Arratíbel JA. Liposarcoma retroperitoneal gigante. Cir Esp. 2005;77:293-5.
Anexos
Anexo 1. Clasificación OMS / 2002, tumores partes blandas.
Tejido adiposo
| ICD-O (726)* | ||
Lipoma | 8850/0 | ||
Lipomatosis | 8850/0 | ||
Lipomatosis del nervio(nerviosa) | 8850/0 | ||
Lipoblastoma-lipoblastomatosis | 8881/0 | ||
Angiolipoma | 8861/0 | ||
Myolipoma | 8890/0 | ||
Lipoma condroide | 8862/0 | ||
Angiomyolipoma extrarenal | 8860/0 | ||
Myelolipoma extra adrenal | 8870/0 | ||
Células fusiformes – pleomorfico | 8857/0 | ||
Hibernoma | 8880/0 | ||
| |||
Tumor lipomatoso atípico / liposarcoma bien diferenciado | 8851/3 | ||
| |||
Liposarcoma desdiferenciado | 8858/3 | ||
Liposarcoma mixoide | 8852/3 | ||
Liposarcoma células redondas | 8853/3 | ||
Liposarcoma pleomorfico | 8854/3 | ||
Liposarcoma tipo mixto | 8855/3 | ||
Liposarcoma sin otra especificación | 8850/3 | ||
Tumor fibroblastico – myofibroblastico
| |||
Fascitis nodular | |||
Fascitis proliferativa | |||
Myositis proliferativa | |||
Myositis osificante | |||
Fascitis isquémica | |||
Elastofibroma | 8820/0 | ||
Hamartoma fibroso de la infancia | |||
Myofibroma/myofibromatosis | 8824/0 | ||
Fibromatosis colli | |||
Fibromatosis hialina juvenil | |||
Fibromatosis de cuerpos de inclusión | |||
Fibroma vaina tendinosa | 8810/0 | ||
Fibroblastoma desmoplastico | 8810/0 | ||
Myofibroblastoma tipo mamario | 8825/0 | ||
Fibroma calcificante aponeurótico | 8810/0 | ||
Angiomyofibroblastoma | 8826/0 | ||
Angiofibroma celular | 9160/0 | ||
Fibroma tipo nucal | 8810/0 | ||
Fibroma Gardner | 8810/0 | ||
Tumor fibroso calcificante | |||
Angiofibroma células gigantes | 9160/0 | ||
| |||
Fibromatosis superficial (plantar – palmar) | 8821/1 | ||
Fibromatosis tipo desmoide | |||
Lipofibromatosis | |||
| |||
Tumor fibroso solitario y hemangiopericitoma | 8815/1 – 9150/1 | ||
Tumor myofibroblastico inflamatorio | 8825/1 | ||
Sarcoma myofibroblastico bajo grado | 8825/3 | ||
Sarcoma fibroblastico mixoinflamatorio | 8811/3 | ||
Fibrosarcoma infantil | 8814/3 | ||
| |||
Fibrosarcoma del adulto | 8810/3 | ||
Mixofibrosarcoma | 8811/3 | ||
Sarcoma fibromixoide de bajo grado – Tumor de células redondas | 8811/3 | ||
Fibrosarcoma epitelioide esclerosante | 8810/3 | ||
Tumor tipo fibrohistocitario Benigno | |||
Tumor de la vaina tendinosa de células gigantes | 9252/0 | ||
Células gigantes tipo difuso | 9251/0 | ||
Histocitoma fibroso profundo benigno | 8830/0 | ||
Intermedio (raramente metastatizante) | |||
Tumor fibrohistocitico plexiforme | 8835/1 | ||
Tumor células gigantes | 9251/1 | ||
Maligno | |||
Histocitoma fibroso maligno pleomorfico – sarcoma indiferenciado pleomorfico | 8830/3 | ||
Histocitoma fibroso maligno células gigantes – sarcoma pleomorfico indiferenciado con células gigantes | 8830/3 | ||
Histocitoma fibroso maligno inflamatorio – sarcoma pleomorfico indiferenciado con inflamación prominente. | 8830/3 | ||
Tumores musculo liso | |||
Angioleiomioma | 8894/0 | ||
Leiomioma profundo | 8890/0 | ||
Leiomioma genital | 8890/0 | ||
Leiomiosarcoma | 8890/3 | ||
Tumores Pericitico (perivascular) | |||
Tumor glomus Tumor glomus maligno | 8711/0 | ||
Miopericitoma | 8713/1 | ||
Tumores del musculo esquelético Benigno | |||
Rabdomioma Tipo adulto Tipo fetal Tipo genital | 8900/0 8904/0 8903/0 8905/0 | ||
Maligno | |||
Rabdomiosarcoma embrionario (células redondas, botroide, anaplasico) | 8910/3 8912/3 8910/3 | ||
Rabdomiosarcoma alveolar (solido, anaplasico) | 8920/3 | ||
Rabdomiosarcoma pleomorfico | 8901/3 | ||
Tumores vasculares | |||
Benigno | |||
Hemangiomas
| 9120/0 9131/0 9121/0 9123/0 9122/0 9132/0 9120/0 | ||
Hemangioma epitelioide | 9125/0 | ||
Angiomatosis | |||
Linfangioma | 9170/0 | ||
Intermedio (localmente agresivo) | |||
hemangioendotelioma Kaposiforme | 9130/1 | ||
Intermedio (raramente metastatizante) | |||
Hemangioendotelioma retiforme | 9135/1 | ||
Angioendotelioma papilar intralinfatico | 9135/1 | ||
Hemangioendotelioma compuesto | 9130/1 | ||
Sarcoma de Kaposi | 9140/3 | ||
Maligno | |||
Hemangioendotelioma epitelioide | 9133/3 | ||
Angiosarcoma partes blandas | 9120/3 | ||
Tumores condro- oseos | |||
Condroma partes blandas | 9220/0 | ||
Condrosarcoma mesenquimatico | 9240/3 | ||
Osteosarcoma extraesqueletico | 9180/3 | ||
Tumores de diferenciación incierta | |||
Benigno | |||
Mixoma intramuscular (incluye variedad celular) | 8840/0 | ||
Mixoma yuxta-articular | 8840/0 | ||
Angiomixoma profundo (agresivo) | 8841/0 | ||
Tumor angioestasico hialinizante pleomorfico | |||
Thimoma hamartomatoso ectópico | 8587/0 | ||
Intermedio (raramente metastatizante) | |||
Histocitoma fibroso angiomatoide | 8836/1 | ||
Tumor fibromixoide osificante (atípico-maligno) | 8842/0 | ||
Tumor mixoide – mioepitelioma – paracondroma | 8940/1 8982/1 9373/1 | ||
Maligno | |||
Sarcoma sinovial | 9040/3 | ||
Sarcoma epitelioide | 8804/3 | ||
Sarcoma partes blandas alveolar | 9581/3 | ||
Sarcoma partes blandas células claras | 9044/3 | ||
Condrosarcoma mixoide extraesqueletico | 9231/3 | ||
PNET/Extraesqueletico Ewing tumor PNET | 9364/3 9260/3 | ||
Tumor desmoplasico de células redondas | 8806/3 | ||
Tumor rabdoide extrarenal | 8963/3 | ||
Mesenquimoma maligno | 8990/3 | ||
PEComa. Neoplasma con diferenciación celular perivascular epitelioide – tumor miomelanocitico células claras | |||
Sarcoma intimal | 8800/3 | ||
*Código de la clasificación internacional de enfermedades oncológicas.
MONOGRAFIA DE ASISTENTE
DE CIRUGIA GENERAL
Autor:
Dr Pablo Valsangiácomo
Clínica Quirúrgica 3. Prof Dr Luis Ruso.
Hospital Maciel. Facultad de Medicina.
Montevideo. Uruguay
Junio 2011
| Página siguiente |